Mobile

Clinical phase II study to evaluate the efficacy and safety of the bispecific antibody blinatumomab (MT103) in adult patients with acute lymphoblastic leukemia (ALL) that did not respond to previous t...

Update Il y a 4 ans
Reference: EUCTR2011-002257-61

Clinical phase II study to evaluate the efficacy and safety of the bispecific antibody blinatumomab (MT103) in adult patients with acute lymphoblastic leukemia (ALL) that did not respond to previous therapy or that relapsed after initially successful previous therapy Estudio Clínico de Fase II para evaluar la eficacia y la seguridad del anticuerpo biespecifico blinatumomab (MT103) en pacientes adultos con leucemia aguda linfoblástica (LLA) que no respondieron a terapia previa o que recayeron despues del éxito de la terapia previa

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate efficacy of blinatumomab in patients with relapsed/refractory B-precursor ALL. Evaluar la eficacia de blinatumomab en pacientes con ALL de precursores de células B con recidiva / que no responde al tratamiento

Inclusion criteria

  • Adult patients with relapsed / refractory B-precursor ALL,Pacientes adultos con LLA de precursores B en recaída o que no responden al tratamiento

Links